BioCentury
ARTICLE | Financial News

Forest beats Street

October 18, 2004 7:00 AM UTC

FRX posted fiscal second quarter EPS of $0.79, beating the Street by $0.03 and up 61% up from $0.49 in the same quarter last year. Before FRX pre-announced strong earnings earlier this month, the Street estimate was $0.63 (see BioCentury Extra, Tuesday Oct. 5, 2004).

Sales rose 38% to $856.7 million from $619.2 million in the second quarter of last year. Antidepressants Lexapro escitalopram and Celexa citalopram contributed $414.9 million and $256.4 million, respectively. For the same period last year, Lexapro sales were $232.4 million and Celexa sales were $282.7 million. Thus, Lexapro sales rose 79% while Celexa sales slipped 9%. ...